In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report), with a price target of $20.00. The company’s shares closed last Friday at $14.55, close to its 52-week high of $14.82.
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.8% and a 36.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and Dermata Therapeutics.
Sensus Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $16.88, representing a 34.2% upside. In a report released yesterday, Alliance Global Partners also maintained a Buy rating on the stock with a $17.50 price target.
Sensus Healthcare’s market cap is currently $242.7M and has a P/E ratio of 9.65.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRTS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
Read More on SRTS:
- Maxim Group Believes Vertex Pharmaceuticals (VRTX) Still Has Room to Grow
- Maxim Group Thinks Seanergy Maritime’s Stock is Going to Recover
- Chesapeake Utilities (CPK) Gets a Buy Rating from Maxim Group
- Tetra Tech (TTEK) Receives a Buy from Maxim Group
- Maxim Group Sticks to Its Buy Rating for New York Mortgage (NYMT)